[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Investor Update - October 18, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Media News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Africa: Brush Your Teeth! Bad Oral Hygiene Linked to Cancer, Heart Attacks and Renal Failure
[The Conversation Africa] It's normal to have bacteria in your mouth. But harmful bacteria have been linked to a host of health problems. Medical scientist Glenda Davison and microbiologist Yvonne Prince, who have researched the oral cavity, explain why it's so important to practise good oral hygiene. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 3, 2023 Category: African Health Tags: Africa Health and Medicine Source Type: news
Risk for Occult Invasive Disease in Oral Cavity Carcinoma Risk for Occult Invasive Disease in Oral Cavity Carcinoma
Surgical excision was associated with improved survival in patients identified with invasive disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 2, 2023 Category: Cancer & Oncology Tags: General Surgery News Source Type: news
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Unveil Wide Range of Innovative Radiation Oncology Research at the 2023 ASTRO Annual Meeting
The institution's latest advancements in radiation treatment of cancer will be showcased in 10 presentations, including four oral presentations NEW BRUNSWICK, N.J., Sept. 29, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 29, 2023 Category: Pharmaceuticals Tags: FVT TDS TRI Source Type: news
Good Oral Health Linked to Improved Survival in Head & Neck Cancer
FRIDAY, Sept. 22, 2023 -- For patients with head and neck squamous cell carcinoma, good oral health is associated with improved survival, according to a study published online Sept. 19 in the Journal of the National Cancer Institute.
Jason Tasoulas,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 22, 2023 Category: Pharmaceuticals Source Type: news
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG. (Source: World Pharma News)
Source: World Pharma News - September 18, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Mayo Clinic Q & amp;A: How to manage dry mouth during cancer care
DEAR MAYO CLINIC: I was diagnosed with oral cavity cancer and will need surgery. I spoke to another patient who underwent a similar procedure, and he said he had many issues afterward with hyposalivation, which affected his eating, speaking and oral health. Can you explain what this is and how do I prevent it? ANSWER: While they are being treated, patients with head and neck cancer often experience xerostomia, or dry mouth, which may be… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 15, 2023 Category: Databases & Libraries Source Type: news
Finding Power in My Panic Attacks
Trouble started in the form of rivulets of sweat dampening the waistband of my underwear. It was a bluebird afternoon in Phoenix in December of 2020, mid 60s, desert dry, and my heart was jackhammering against my ribcage. Breathing felt like I was sucking air through a stir straw. A small ABC News crew was arrayed before me, ready to broadcast the report I’d written that day, but with my vision narrowed to a needle’s eye, I could barely see them. I tried to swallow away the sandiness in my mouth but realized I’d forgotten how.
[time-brightcove not-tgx=”true”]
“I can’t swallow!...
Source: TIME: Health - September 12, 2023 Category: Consumer Health News Authors: Matt Gutman Tags: Uncategorized freelance Source Type: news
Furious dentist hits out NHS dental crisis after patient unable to get an appointment for years is diagnosed with oral cancer - and shares warning signs of the disease
Dr Emi Mawson, a dentist in Cornwall, revealed that her patient finally secured an appointment last month, during which she spotted signs of oral cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - September 11, 2023 Category: Consumer Health News Source Type: news
The Ca2+ channel ORAI1 is a regulator of oral cancer growth and nociceptive pain | Science Signaling
The Ca2+ channel ORAI1 promotes the growth of oral cancer cells and the pain they induce. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 5, 2023 Category: Science Source Type: news
Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Media News - September 1, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Investor Update - September 1, 2023 Category: Pharmaceuticals Source Type: news
John Farnham Given ‘All Clear’ Following Cancer Battle: ‘Bring on 2024’
John Farnham is cancer-free and feeling like “the luckiest man alive.” The legendary Australian singer shared the good news to mark the anniversary of a marathon operation to remove a cancerous growth from his mouth. “It’s been a year since my first surgery and to be honest I’ve lost count as to…#johnfarnham #australian #farnham #voice #kentmusicreport #officialukchart #menatworks #downunder #whisperingjack #aria (Source: Reuters: Health)
Source: Reuters: Health - August 24, 2023 Category: Consumer Health News Source Type: news
